HOLON, Israel, July 21, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, today announced that the Company will host a
conference call at 10:00 AM ET on
Tuesday, August 2, 2016 to review the
second quarter 2016 results. The quarterly results will be released
on the Company's website (www.cgen.com) prior to the conference
call.
To access the conference call, please dial 1-888-407-2553 from
the US, or +972-3-918-0685 internationally. The call will also
be available via live webcast through Compugen's website, located
at the following link. A replay of the conference call will be
available beginning approximately two hours after the completion of
the live conference call. To access the replay, please dial
1-888-326-9310 from the US or +972-3-925-5925 internationally. The
replay will be available through August 4,
2016.
About Compugen
Compugen is a leading therapeutic discovery company utilizing
its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics.
The primary focus of the Company's current pipeline is on immune
checkpoint target candidates discovered by the Company, potentially
providing the basis for a next wave of therapeutics for cancer
immunotherapy. Compugen's business model is based on selectively
entering into collaborations for its novel target candidates and
drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Israel, with
R&D facilities in Israel and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company's novel target candidates. For additional information,
please visit Compugen's corporate website at
http://www.cgen.com.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.